MK-677 (Ibutamoren): What to Expect, Week-by-Week First Month

The direct answer

Ibutamoren (MK-677) stimulates endogenous GH release through the ghrelin receptor rather than replacing GH directly, and its most reproducible early effects are increased appetite (within days) and changes in sleep architecture (within about a week), both consistent with small pharmacology studies in healthy and older adults. It has no FDA-approved indication, no established safe dosing range, and no validated protocol for when to reduce or stop it; anyone using it is doing so off the basis of research data, not a cleared drug label, and should treat any specific numeric threshold found online (a particular glucose cutoff, a specific percentage lean-mass gain) as unverified unless a clinician has checked it against the primary literature.

The useful question for a first-time user is not "what will happen each week" but "what specific, falsifiable signal would tell me to stop or get evaluated", because the trial evidence supports general directionality (appetite up, sleep architecture shifts, IGF-1 rises) far better than it supports a precise timeline or dosing algorithm.

What ibutamoren is, and what it is not

Ibutamoren (MK-677) is a small molecule that activates the ghrelin receptor, which in turn stimulates pituitary GH release and raises downstream IGF-1. It is taken orally, unlike recombinant human growth hormone (rhGH), which is injected. It is not a selective androgen receptor modulator (SARM) despite frequent mislabeling online: it does not bind androgen receptors and has a different mechanism and side-effect profile than SARMs.

MK-677 has never completed a Phase III trial for any indication, and the FDA has not approved it as a drug. Products sold as "MK-677" in supplement or research-chemical markets are not manufactured under FDA drug-quality oversight, and regulators have separately warned in general terms that some products marketed as supplements contain unapproved peptide and hormone-related ingredients that are not what the label claims. That warning is general to the supplement category and is not a specific finding about any one MK-677 product; readers should not read a specific contamination claim into it.

Growth hormone products with actual FDA approval (for conditions such as adult GH deficiency) exist under prescription, brand-name formulations, and are dispensed as injections under physician supervision. A general list of FDA-approved drug products can be checked directly through the FDA's own database rather than through secondary sources (FDA Orange Book / drug approvals database).

What is established, what is plausible, and what is not established

Established, from published human pharmacology studies: MK-677 raises IGF-1 in healthy and older adults with continued daily oral dosing, and short courses (about a week) have been associated with changes in sleep architecture (more slow-wave and REM sleep) in small controlled studies. GH secretagogues as a class are known to promote renal sodium retention, which explains early water-weight gain.

Plausible but not adequately established by the material available for this article: exact percentage changes in IGF-1 or glucose at specific weeks, a reliable timeline for when insulin sensitivity changes and by how much, whether joint comfort or collagen effects are clinically meaningful at typical doses, and whether any dosing schedule (nightly versus morning) meaningfully changes outcomes rather than just subjective grogginess.

Not established: a validated week-by-week symptom map, a specific numeric IGF-1 or glucose threshold that should trigger a dose change (beyond standard, non-drug-specific glucose thresholds used generally in diabetes care), long-term cancer risk in humans at typical recreational or research doses, and any effect in combination with resistance training in healthy young adults, since that population has not been the subject of published randomized trials in the material reviewed here.

Where earlier drafts of consumer material have cited specific percentages (for example, "IGF-1 rose 60%") or attributed a direct quotation to a specific guideline, those figures require verification against the original paper before publication and are not repeated here as settled facts.

Who should not use it, and why

People with active or recent malignancy are generally advised against GH-stimulating interventions of any kind, because IGF-1 signaling can support tumor-cell growth; this is a standard principle in endocrinology guidance on GH therapy generally, and the same caution is reasonably extended to a compound that substantially raises endogenous GH and IGF-1, even though ibutamoren-specific guidelines do not exist.

People with poorly controlled type 2 diabetes or significant insulin resistance should be cautious, since GH-axis stimulation is understood mechanistically to reduce insulin sensitivity, and this compound has not been studied in that population in a way that would establish a safe approach.

Anyone with known pituitary disease, a personal or strong family history of acromegaly-related complications, or unexplained new numbness/tingling in the hands (which can signal median-nerve compression from GH-mediated fluid retention) should get evaluated before continuing.

Week 1 (days 1 to 7): appetite and sleep are the first signals

The most consistently reported early change is in sleep quality: users and small studies describe more vivid dreams, feeling "heavier" during sleep, and fewer night wakings. This is broadly consistent with the class effect of GH secretagogues increasing slow-wave and REM sleep, though the exact magnitude and duration reported in any single small trial should be treated as illustrative rather than a guarantee for any individual.

Appetite increase is ghrelin-receptor mediated and commonly starts within the first two to three days. For someone on a fat-loss plan, this can be disruptive enough to derail dietary targets and is worth planning for rather than being surprised by.

Water retention is also common in week 1, generally described as one to a few kilograms of scale weight that is fluid, not fat or muscle, related to GH-driven renal sodium retention. Mild swelling in the hands or feet on waking can accompany this.

No published dosing schedule for MK-677 has FDA or guideline backing. Nighttime dosing is commonly recommended on the physiological logic that the largest natural GH pulse occurs shortly after sleep onset, but this rationale has not been validated as improving outcomes in a controlled trial; it is a plausible extrapolation, not an established finding.

Week 2 (days 8 to 14): appetite peaks, fatigue can appear, check glucose if at risk

Appetite stimulation is often reported as most pronounced in week 2. Protein-dense meals are understood physiologically to blunt ghrelin more than carbohydrate-heavy meals, so front-loading protein can help manage hunger, though this is general nutrition physiology rather than an MK-677-specific finding.

Some users report afternoon fatigue in week 2. A plausible mechanism is a mild cortisol response accompanying GH pulses, but this has not been rigorously mapped, and the fatigue commonly described as resolving by week 3 is anecdotal rather than a trial-confirmed pattern.

If someone is prediabetic or has metabolic syndrome, checking fasting glucose around this point is a reasonable precaution, because reduced insulin sensitivity with GH-axis stimulation is mechanistically expected and has been reported in small studies of GH secretagogues, even though the exact magnitude at two weeks for any individual product or dose has not been reliably established here.

Week 3 (days 15 to 21): the acute burden usually softens

Appetite typically remains elevated but feels more manageable, and water retention tends to plateau as the kidneys adjust to the new sodium-handling set point. Reports of mild joint fullness or reduced joint discomfort in this window are plausibly related to IGF-1's role in connective-tissue turnover, but this connection has not been demonstrated specifically for MK-677 users at typical doses and should be read as a hypothesis, not a confirmed effect.

Sleep-related vivid dreaming commonly becomes less pronounced by week 3, while the underlying increase in slow-wave sleep is generally reported as persisting for as long as dosing continues in the short studies that have measured it.

Week 4 (days 22 to 30): what a first real checkpoint should look like

By four weeks, some detectable change in lean mass on DEXA scanning is plausible if IGF-1 has been meaningfully elevated, based on the general physiology of sustained GH-axis stimulation, but no reliable individual-level number can be quoted here as an expectation, and much of the earlier scale-weight change is still confounded by water retention resolving.

A reasonable four-week checkpoint includes fasting glucose, fasting insulin if available, and IGF-1, compared against a standard age- and sex-adjusted reference range obtained from the lab performing the test, since "normal" IGF-1 varies by age. If water retention has not improved by four weeks, or if new symptoms (persistent hand numbness, unexplained swelling, resting heart rate changes) have appeared, that is a reasonable point to pause and get a clinical evaluation rather than continue self-adjusting the dose.

Side effects: what is expected versus what should prompt stopping

Commonly reported and usually self-limited

• Increased appetite, typically starting within 48 to 72 hours
• Water retention or mild peripheral swelling, typically most noticeable in the first week and easing over three to four weeks
• Vivid or intense dreams in the first one to two weeks
• Morning grogginess, especially with morning dosing

Reasonable triggers for dose reduction or pause, pending clinician input

• Fasting glucose rising into the prediabetes range (100 mg/dL / 5.6 mmol/L or above) in someone previously normoglycemic
• IGF-1 above the age-adjusted upper limit of normal on repeat testing
• Persistent swelling beyond four weeks
• New numbness or tingling in the hands, which can reflect nerve compression from fluid retention and is well documented as a complication of GH excess in the acromegaly literature, even though acromegaly involves far higher and more sustained GH/IGF-1 exposure than typical MK-677 use

Reasons to stop and seek care

• Any new finding of malignancy or a suspicious lesion during use
• Fasting glucose reaching the diabetes threshold (126 mg/dL / 7.0 mmol/L)
• Any pituitary abnormality identified on imaging
• Significant worsening of pre-existing diabetes control

These thresholds for glucose are standard clinical diagnostic cutoffs used broadly in diabetes care, not thresholds derived from an MK-677-specific trial; they are used here as reasonable, general safety markers rather than a validated drug-specific protocol.

MK-677 versus prescription growth hormone: what actually differs

The pulsatile-versus-flat GH release distinction is a mechanistic description of how each approach works, not a claim that one is proven safer than the other in practice, since MK-677 has not undergone the large, long-duration safety trials that prescription GH products have.

Decision framework: what changes what you should actually do

This is not a dosing protocol. It is a way to sort the signals a first-month user is likely to notice into "expected, keep watching," "pause and check," and "stop and get evaluated," because that distinction is what the underlying evidence can actually support, unlike a precise symptom calendar.

The common thread: most of the "expected" column reflects mechanistically plausible, class-consistent effects seen in small studies, while the "stop and get evaluated" column is built from standard clinical red flags (glucose thresholds, nerve symptoms, imaging findings) rather than anything specific to MK-677 trial data, because MK-677-specific stopping rules have not been established in the literature.

Baseline and follow-up checks worth discussing with a clinician

A reasonable baseline panel to discuss before starting includes fasting glucose, hemoglobin A1c, fasting insulin, a complete metabolic panel, and IGF-1, with a repeat of fasting glucose and IGF-1 around four weeks. This is a sensible monitoring approach rather than an FDA-cleared or guideline-mandated protocol, since no such protocol exists for this compound.

Regulatory and doping context (dated to 2025)

MK-677 has no FDA-approved indication as of 2025, and no active New Drug Application is known to be under review for it. Because it is not manufactured under drug-quality oversight when sold outside a research setting, product purity and actual dose content cannot be assumed to match the label. Growth hormone secretagogues, including ghrelin-receptor agonists, are generally categorized by anti-doping authorities under peptide hormone and growth factor prohibitions; athletes subject to testing should check the current prohibited list directly with their sport's anti-doping body rather than relying on secondary summaries, since prohibited-list details can change year to year.

References

1. U.S. Food and Drug Administration. Drug approvals database (for verifying FDA-approved GH products and current approval status). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

Earlier versions contained specific figures regarding MK-677's effects on IGF-1 levels and muscle mass, along with direct quotations from clinical guidelines, that could not be traced to verified primary sources and have therefore been replaced with appropriately cautious language. Prior to publishing, the editor should independently confirm the Murphy et al., Copinschi et al., Nass et al., and Chapman et al. studies via PubMed and verify any percentages, cutoff values, or direct quotes against these original sources before reintroducing them.